Znamy uboczne skutki stosowania wadliwych szczepionek na covid-19
pacjentom, którzy zmarli wskutek szczepienia
Ale znamy tylko dla Stanów, dzięki Robertowi Kennedy'emu, Jr
https://www.medalerts.org/vaersdb/findfield.php?EVENTS=on&PAGENO=3733&PERPAGE=10&ESORT=&REVERSESORT=&VAX=(COVID19)&DIED=Yes
From the 8/30/2024 release of VAERS data:
Found 37,390 cases where Vaccine is COVID19 and Patient Died
Government Disclaimer on use of this data
Case Details
This is page 3733 out of 3,739
Result pages: prev 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733
3734 3735 3736 3737 3738 3739 next
VAERS ID: 2783584 (history)
Form: Version 2.0
Age:
Sex: Female
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-08
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / UNK
- / -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: MYPFIZER INC202400232354
Write-up: Death; Safety information originally reported under
manufacturer case AER number 202200501613 has been nullified and
re-entered under this new manufacturer report number AER number
202400232354. This is a spontaneous report received from a Pharmacist
from Regulatory Authority. Regulatory number: 21-06-02093A (National
Pharmaceutical Regulatory Agency). A 82 year-old female patient received
bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose number unknown,
single for covid-19 immunisation. The patient''s relevant medical
history and concomitant medications were not reported. The following
information was reported: DEATH (death, medically significant) with
onset 5 days after the suspect product administration, outcome "fatal",
described as "Death". The patient date of death was 5 days after
vaccination. The reported cause of death was "Death". It was unknown if
an autopsy was performed. Pharmacist considered relatedness as
Unclassifiable for Death. No follow-up attempts are possible;
information about lot/batch number cannot be obtained. No further
information is expected. Follow-up (07Aug2024): This is a follow-up
report to notify that the case 202200501613 and 202400232354 are
duplicates. All subsequent follow-up information will be reported under
manufacturer report number 202400232354.; Reported Cause(s) of Death:
Death
VAERS ID: 2783601 (history)
Form: Version 2.0
Age:
Sex: Male
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-08
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 2 -
/ -
Administered by: Other Purchased by: ?
Symptoms: Acquired haemophilia, Activated partial thromboplastin time,
Alanine aminotransferase, Anti factor VIII antibody test, Aspartate
aminotransferase, Blood bilirubin, Blood creatinine, Blood culture,
Blood pressure measurement, Computerised tomogram abdomen, Computerised
tomogram head, Factor VIII activity test, Glomerular filtration rate,
Haemoglobin, Investigation, Prothrombin time, Respiratory rate, Urine
output, White blood cell count
SMQs:, Haemorrhage laboratory terms (broad)
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, ? days
Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Diabetes
mellitus; Dyslipidemia; Hypertension
Allergies:
Diagnostic Lab Data: Test Name: activated partial thromboplastin time
(aPTT); Test Result: 74.7 s; Test Name: activated partial thromboplastin
time (aPTT); Result Unstructured Data: Test Result:Greater than 180
seconds; Comments: After admission; Test Name: alanine aminotransferase;
Result Unstructured Data: Test Result:92 IU/l; Test Name: FVIII antibody
test; Test Result: Positive ; Comments: confirming the diagnosis of AHA;
Test Name: FVIII antibody titer; Result Unstructured Data: Test
Result:8.49; Comments: Unit: Bethesda units/mL; Test Name: FVIII
antibody titer; Result Unstructured Data: Test Result:0.84; Comments:
Unit: Bethesda units/mL, decreased; Test Name: FVIII antibody titer;
Result Unstructured Data: Test Result:1.85; Comments: Unit: BU/mL,
rose/after 43 days of methylprednisolone and cyclophosphamide; Test
Name: FVIII antibody titer; Result Unstructured Data: Test Result:1.13;
Comments: Unit: BU/mL, after 3 weeks of treatment; Test Name: FVIII
antibody titer; Result Unstructured Data: Test Result:0.32; Comments:
Unit: BU/mL, After 1 month, the titer of FVIII inhibitor decreased
further; Test Name: Aspartate aminotransferase; Result Unstructured
Data: Test Result:76 IU/l; Test Name: total bilirubin; Test Result: 5.59
mg/dl; Test Name: creatinine level; Test Result: 1.79 mg/dl; Test Name:
blood culture; Result Unstructured Data: Test Result:Enterobacter
cloacae complex was identified; Comments: 5 days before the death; Test
Name: blood pressure; Result Unstructured Data: Test Result:95/56 mmHg;
Test Name: Abdominopelvic computed tomography (CT) scans; Result
Unstructured Data: Test Result:revealed a large 20 cm-sized hematoma
along; Comments: the left psoas muscle and additional intramuscular
bleeding in the right iliopsoas muscle. The scans also showed extensive
bleeding in the peritoneal cavity, particularly around the liver,
spleen, and flanks.; Test Name: Abdominopelvic computed tomography (CT)
scans; Result Unstructured Data: Test Result:intracranial hemorrhage had
resolved, and the size; Comments: of the intraperitoneal hematoma had
decreased Approximately ten weeks later/after treatment; Test Name:
brain CT; Result Unstructured Data: Test Result:intracranial hemorrhage
in the left basal ganglia; Comments: and frontoparietal lobe; Test Name:
brain CT; Result Unstructured Data: Test Result:intracranial hemorrhage
had resolved, and the size; Comments: of the intraperitoneal hematoma
had decreased Approximately ten weeks later/after treatment; Test Name:
FVIII activity; Result Unstructured Data: Test Result:Less than 1.5%;
Comments: Initial FVIII activity was undetectable, confirming the
diagnosis of AHA; Test Name: FVIII activity; Result Unstructured Data:
Test Result:25%; Comments: increased, after 2 weeks of
immunosuppression; Test Name: estimated glomerular filtration rate;
Result Unstructured Data: Test Result:41.4; Comments: Unit: mL/min; Test
Name: hemoglobin; Result Unstructured Data: Test Result:6.1 g/dl;
Comments: hemoglobin concentration; Test Name: 1:1 mixing study; Result
Unstructured Data: Test Result:no significant correction of the aPTT;
Test Name: examination; Result Unstructured Data: Test Result:notable
mass was palpable in the left abdominal; Comments: quadrant; Test Name:
prothrombin time; Test Result: 17.2 s; Test Name: prothrombin time; Test
Result: 16.9 s; Comments: After admission; Test Name: respiratory rate;
Result Unstructured Data: Test Result:increased; Test Name: urine
output; Result Unstructured Data: Test Result:decreased; Test Name:
white blood cell count; Result Unstructured Data: Test Result:18300 /mm3
CDC Split Type: KRPFIZER INCPV20240010225
Write-up: Severe acquired hemophilia; This is a literature report for
the following literature source(s):. A 56-year-old male patient received
BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for
covid-19 immunisation. The patient''s relevant medical history included:
"hypertension" (unspecified if ongoing); "dyslipidemia" (unspecified if
ongoing); "diabetes mellitus" (unspecified if ongoing). The patient''s
concomitant medications were not reported. Vaccination history included:
Covid-19 vaccine (DOSE 1, Unknown Manufacturer), for COVID-19
immunisation. The following information was reported: ACQUIRED
HAEMOPHILIA (death, hospitalization, medically significant), 15 days
after the suspect product(s) administration, outcome "fatal", described
as "Severe acquired hemophilia". The event "severe acquired hemophilia"
required emergency room visit. Clinical course: A 56-year-old man with a
history of hypertension, dyslipidemia, and diabetes mellitus was
transferred to their hospital after receiving his second dose of the
COVID-19 vaccine (BNT162b2) 2 weeks earlier. Upon arrival at the
emergency department, he exhibited severe headaches and a drowsy
mentality, along with significant abdominal distension. A notable mass
was palpable in the left abdominal quadrant upon examination. His vital
signs revealed a blood pressure of 95/56 mmHg, an increased respiratory
rate, and decreased urine output. Abdominopelvic computed tomography
(CT) scans revealed a large 20 cm-sized hematoma along the left psoas
muscle and additional intramuscular bleeding in the right iliopsoas
muscle. The scans also showed extensive bleeding in the peritoneal
cavity, particularly around the liver, spleen, and flanks. Laboratory
tests indicated an activated partial thromboplastin time (aPTT) of 74.7
seconds and a prothrombin time (PT) of 17.2 seconds. A 1:1 mixing study
revealed no significant correction of the aPTT. Initial FVIII activity
was undetectable (less than 1.5 percentage) and FVIII antibody test was
positive, confirming the diagnosis of AHA. They considered the mild
prolongation of PT results from severe coagulation factor consumption
after a large amount of intraabdominal bleeding. His hemoglobin
concentration was 6.1 g/dL, necessitating a transfusion of packed red
blood cells. Additional significant findings included a white blood cell
count of 18,300/mm3 and a creatinine level of 1.79 mg/dL (estimated
glomerular filtration rate of 41.4 mL/min). His total bilirubin was 5.59
mg/dL, alanine and asparate aminotransferase was 92 and 76 U/L,
respectively. A rapid decline in mental status was observed, attributed
to intracranial hemorrhage in the left basal ganglia and frontoparietal
lobe as detected by brain CT. After admission, an aPTT was greater than
180 seconds and a PT was 16.9 seconds. FVIII antibody titer was 8.49
Bethesda units/mL, Mechanical ventilation and continuous renal
replacement therapy were initiated in the ICU. Following transfer to
their center, recombinant factor VIIa (rFVIIa; NovoSeven) was
administered at 90 ug/kg intravenously every 2 hours to control active
bleeding. However, persistent oral bleeding and hemoptysis through the
endotracheal tube continued for several days. The treatment was switched
from rFVIIa to factor 8 inhibitor bypassing activity (FEIBA, 5000 IU
every 8 hours). Approximately ten weeks later, the intracranial
hemorrhage had resolved, and the size of the intraperitoneal hematoma
had decreased, as confirmed by follow-up brain and abdominal CT.
Methylprednisolone at 65 mg (equivalent to prednisolone 1 mg/kg) daily
and cyclophosphamide at 2 mg/kg daily were administered intravenously to
eliminate the autoantibody. The titer of the FVIII inhibitor decreased
to 0.84 Bethesda Units (BU)/mL, and FVIII activity increased to 25%
after 2 weeks of immunosuppression. However, the titer of FVIII
inhibitor rose to 1.85 BU/mL after 43 days of methylprednisolone and
cyclophosphamide. They first changed methylprednisolone todexamethasone
20 mg (approximate to prednisolone 2 mg/kg), and the dose of
dexamethasone was tapered until 6mg. The titer of the FVIII inhibitor
decreased to 1.13 BU/mL after 3 weeks of treatment with dexamethasone
and cyclophosphamide. They decided to change cyclophosphamide to
cyclosporine to eradicate FVIII inhibitors because few cases showed
complete remission with cyclosporine after cyclophosphamide failure.
After 1 month, the titer of FVIII inhibitor decreased further to 0.32
BU/mL. Despite the cessation of active bleeding, the patient succumbed
to sepsis after 14 weeks of hospitalization. Cyclosporine 100 mg bid and
dexamethasone 6mg was administered at the time of death. Meropenem 1 g
per 8 hours was continuously administered from the admission and
vancomycin 1 g per 24 hours was administered for 30 days to control the
infections. However, Enterobacter cloacae complex was identified from
the blood culture 5 days before the death. The information on the
batch/lot number for BNT162b2 has been requested and will be submitted
if and when received.; Sender''s Comments: Based on the information
provided , temporal association and the known effects of the suspect
drug, a possible contributory role of the suspect drug in triggering the
onset of the serious event Acquired hemophilia cannot be excluded. The
impact of this report on the benefit-risk profile of the Pfizer product
and on the conduct of the study is evaluated as part of Pfizer
procedures for safety evaluation, including the review and analysis of
aggregate data for adverse events. Any safety concern identified as part
of this review, as well as any appropriate action in response, will be
promptly notified to regulatory authorities, Ethics Committees, and
Investigators, as appropriate.; Reported Cause(s) of Death: sepsis
VAERS ID: 2783691 (history)
Form: Version 2.0
Age:
Sex: Male
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / UNK
- / -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AUPFIZER INC202400232815
Write-up: died; Safety information originally reported under
manufacturer case 202200028696 has been nullified and re-entered under
this new manufacturer report number 202400232815. This is a spontaneous
report received from a contactable reporter (Other HCP) from medical
information team. A male patient received bnt162b2 (COMIRNATY)
(Batch/Lot number: unknown) as dose number uknown, single for covid-19
immunisation. The patient''s relevant medical history and concomitant
medications were not reported. The following information was reported:
DEATH (death, medically significant), outcome "fatal", described as
"died". Therapeutic measures were taken as a result of death. The
patient date of death was unknown. The reported cause of death was
"died". It was not reported if an autopsy was performed. Additional
information: Something wasn''t right when 20 times more people are in
hospital with vaccine injuries compared to Covid itself. The guy
(patient) next to reporter in the bed in hospital died last night and he
had the vaccine. No follow-up attempts are possible; information about
lot/batch number cannot be obtained. No further information is expected.
Follow-up (07Aug2024): This is a follow-up report to notify that the
case 202200028696 and 202400232815 are duplicates. All subsequent
follow-up information will be reported under manufacturer report number
202400232815.; Sender''s Comments: The information currently provided is
too limited to make a meaningful medical assessment. However, per
company causality assessment guidance, the event of death with unknown
cause is assessed as related until the cause of death is clarified. The
impact of this report on the benefit/risk profile of the Pfizer product
is evaluated as part of Pfizer procedures for safety evaluation,
including the review and analysis of aggregate data for adverse events.
Any safety concern identified as part of this review, as well as any
appropriate action in response, will be promptly notified to RAs, Ethics
Committees, and Investigators, as appropriate.; Reported Cause(s) of
Death: died
VAERS ID: 2783692 (history)
Form: Version 2.0
Age:
Sex: Male
Location: Foreign
Vaccinated: 2021-11-25
Onset: 2021-12-07
Days after vaccination: 12
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 -
/ -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 2021-12-07
Days after onset: 0
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AUPFIZER INC202400232824
Write-up: Adverse event following immunisation; Safety information
originally reported under manufacturer case 202200349249 has been
nullified and re-entered under this new manufacturer report number
202400232824. This is a spontaneous report received from a contactable
reporter(s) (Other HCP) from Regulatory Authority. Regulatory number:
714469. A 56 (unit not reported) male patient received BNT162B2
(COMIRNATY, solution for injection), administration date 25Nov2021
(Batch/Lot number: unknown) as dose 1, single for COVID-19 immunisation.
The patient''s relevant medical history and concomitant medications were
not reported. The following information was reported: DEATH (death) with
onset 07Dec2021, outcome "fatal", described as "Adverse event following
immunisation". The patient date of death was 07Dec2021. The reported
cause of death was "Adverse event following immunisation". The onset of
latency of the event from the suspect drug was 12 days. No follow-up
attempts are possible; information about lot/batch number cannot be
obtained. No further information is expected. Amendment: This follow up
report is being submitted to amend previously reported information:
"Adverse event following immunization" was recoded to unknown cause of
death. Follow-up (07Aug2024): This is a follow-up report to notify that
the case 202400232824 and 202200349249 are duplicates. All subsequent
follow-up information will be reported under manufacturer report number
202400232824.; Reported Cause(s) of Death: Adverse event following
immunisation
VAERS ID: 2783693 (history)
Form: Version 2.0
Age:
Sex: Male
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / UNK
- / -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AUPFIZER INC202400232835
Write-up: died in his sleep; Safety information originally reported
under manufacturer case PV202200025337 has been nullified and re-entered
under this new manufacturer report number 202400232835. This is a
spontaneous report received from a contactable reporter(s) (Consumer or
other non HCP). An adolescent male patient received COVID-19 Vaccine -
Manufacturer Unknown, as dose number unknown, single (Batch/Lot number:
unknown) for covid-19 immunisation. The patient''s relevant medical
history and concomitant medications were not reported. The following
information was reported: DEATH (death, medically significant), outcome
"fatal", described as "died in his sleep". The date and cause of death
for the patient were unknown. No follow-up attempts are possible;
information about batch/lot number cannot be obtained. No further
information is expected. Amendment: This follow-up report is being
submitted to amend previous information: Amended the narrative
information (No follow-up attempts are possible; information about
batch/lot number cannot be obtained. No further information is
expected). Follow-up (07Aug2024): This is a follow-up report to notify
that the case 202400232835 and PV202200025337 are duplicates. All
subsequent follow-up information will be reported under manufacturer
report number 202400232835.; Reported Cause(s) of Death: died in his
sleep
VAERS ID: 2783694 (history)
Form: Version 2.0
Age:
Sex: Female
Location: Foreign
Vaccinated: 2022-01-21
Onset: 2022-02-28
Days after vaccination: 38
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 -
/ -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AUPFIZER INC202400232840
Write-up: Adverse event following immunisation; Safety information
originally reported under manufacturer case 202200418105 has been
nullified and re-entered under this new manufacturer report number
202400232840. This is a spontaneous report received from a contactable
reporter(s) (Other HCP) from Regulatory Authority. Regulatory number:
718761). A 72 year-old female patient received bnt162b2 (COMIRNATY),
administration date 21Jan2022 (Batch/Lot number: unknown) as dose 1,
single for covid-19 immunisation. The patient''s relevant medical
history and concomitant medications were not reported. The following
information was reported: DEATH (death, medically significant) with
onset 28Feb2022, outcome "fatal", described as "Adverse event following
immunisation". The patient date of death was unknown. The reported cause
of death was "Adverse event following immunisation". No follow-up
attempts are possible; information about lot/batch number cannot be
obtained. No further information is expected. Follow-up (07Aug2024):
This is a follow-up report to notify that the case 202400232840 and
202200418105 are duplicates. All subsequent follow-up information will
be reported under manufacturer report number 202400232840.; Reported
Cause(s) of Death: Adverse event following immunisation
VAERS ID: 2783695 (history)
Form: Version 2.0
Age:
Sex: Female
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 -
/ -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: AUPFIZER INC202400232851
Write-up: Adverse event following immunisation; Safety information
originally reported under manufacturer case 202200809921 has been
nullified and re-entered under this new manufacturer report number
202400232851. This is a spontaneous report received from a contactable
reporter(s) (Other HCP) from Regulatory Authority. Regulatory number:
738905. A 48-year-old female patient received BNT162b2 (COMIRNATY), as
dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation.
The patient''s relevant medical history and concomitant medications were
not reported. The following information was reported: DEATH (death),
outcome "fatal", described as "Adverse event following immunisation".
The date and cause of death for the patient were unknown. It was not
reported if an autopsy was performed. No follow-up attempts are
possible; information about lot/batch number cannot be obtained. No
further information is expected. Follow-up (07Aug2024): This is a
follow-up report to notify that the case 202200809921 and 202400232851
are duplicates. All subsequent follow-up information will be reported
under manufacturer report number 202400232851.; Reported Cause(s) of
Death: Adverse event following immunisation
VAERS ID: 2783710 (history)
Form: Version 2.0
Age:
Sex: Male
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / UNK
- / -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: CHPFIZER INC202400232639
Write-up: 2 or 3 of his friends (all men) died after receiving 2 or 3
doses of the COMIRNATY vaccine; Safety information originally reported
under manufacturer case 202200916026 has been nullified and re-entered
under this new manufacturer report number 202400232639. This is a
spontaneous report received from a contactable reporter(s) (Consumer or
other non HCP) from medical information team. A male patient received
BNT162b2 (COMIRNATY), as dose number unknown, single (Batch/Lot number:
unknown) for covid-19 immunisation. The patient''s relevant medical
history was not reported. There were no concomitant medications. The
following information was reported: DEATH (death), outcome "fatal",
described as "2 or 3 of his friends (all men) died after receiving 2 or
3 doses of the COMIRNATY vaccine". The date and cause of death for the
patient were unknown. Clinical course: The male person called to find
out why the laboratory did not communicate to the media about the
Comirnaty vaccine and in particular about its composition. He said his
father was a cancer researcher and advised him not to get vaccinated.
The caller reported that 2 or 3 of his friends (all men) died after
receiving 2 or 3 doses of the COMIRNATY vaccine. He specified that he
was not vaccinated. The information on the batch/lot number for BNT162b2
has been requested and will be submitted if and when received. Follow-up
(28Jul2022): Follow-up attempts are completed. No further information is
expected. Follow-up (07Aug2024): This is a follow-up report to notify
that the case 202200916026 and 202400232639 are duplicates. All
subsequent follow-up information will be reported under manufacturer
report number 202400232639.; Sender''s Comments: Linked Report(s) :
CH-PFIZER INC-202200915038 same reporter drug and event, different
patient;CH-PFIZER INC-202200916027 same reporter drug and event,
different patient;; Reported Cause(s) of Death: 2 or 3 of his friends
(all men) died after receiving 2 or 3 doses of the COMIRNATY vaccine
VAERS ID: 2783711 (history)
Form: Version 2.0
Age:
Sex: Male
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / UNK
- / -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: CHPFIZER INC202400232737
Write-up: 2 or 3 of his friends (all men) died after receiving 2 or 3
doses of the COMIRNATY vaccine; Safety information originally reported
under manufacturer case 202200915038 has been nullified and re-entered
under this new manufacturer report number 202400232737. This is a
spontaneous report received from a contactable reporter(s) (Consumer or
other non HCP) from medical information team. A male patient received
BNT162b2 (COMIRNATY), as dose number unknown, single (Batch/Lot number:
unknown) for covid-19 immunisation. The patient''s relevant medical
history and concomitant medications were not reported. The following
information was reported: DEATH (death), outcome "fatal", described as
"2 or 3 of his friends (all men) died after receiving 2 or 3 doses of
the COMIRNATY vaccine". The date and cause of death for the patient were
unknown. Clinical information: The reporter said his father was a cancer
researcher and advised him not to get vaccinated. The caller reported
that 2 or 3 of his friends (all men) died after receiving 2 or 3 doses
of the COMIRNATY vaccine. He specified that he was not vaccinated. No
more information available. The information on the batch/lot number for
BNT162b2 has been requested and will be submitted if and when received.
Follow-up (28Jul2022): Follow-up attempts are completed. No further
information is expected. Follow-up (07Aug2024): This is a follow-up
report to notify that the case 202400232737 and 202200915038 are
duplicates. All subsequent follow-up information will be reported under
manufacturer report number 202400232737.; Sender''s Comments: Linked
Report(s) : CH-PFIZER INC-202200916027 same reporter drug and event,
different patient;CH-PFIZER INC-202200916026 same reporter drug and
event, different patient;; Reported Cause(s) of Death: 2 or 3 of his
friends (all men) died after receiving 2 or 3 doses of the COMIRNATY
vaccine
VAERS ID: 2783715 (history)
Form: Version 2.0
Age:
Sex: Female
Location: Foreign
Vaccinated: 0000-00-00
Onset: 0000-00-00
Submitted: 0000-00-00
Entered: 2024-08-09
Vaccination / Manufacturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / UNK
- / -
Administered by: Other Purchased by: ?
Symptoms: Death
SMQs:
Life Threatening? No
Birth Defect? No
Died? Yes
Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: COPFIZER INC202400232891
Write-up: her best friend received the Covid vaccine and she had died;
Safety information originally reported under manufacturer case
202200122747 has been nullified and re-entered under this new
manufacturer report number 202400232891. This is a spontaneous report
received from a Consumer or other non HCP, Program ID. A female patient
(unknown if pregnant) received BNT162b2 (BNT162B2), as dose number
unknown, single (Batch/Lot number: unknown) for covid-19 immunisation.
The patient''s relevant medical history and concomitant medications were
not reported. The following information was reported: DEATH (death,
medically significant), outcome "fatal", described as "her best friend
received the Covid vaccine and she had died". The patient date of death
was unknown. The reported cause of death was "Patient died". It was not
reported if an autopsy was performed. Clinical course was reported as
follow: Reporter also stated that the Covid vaccine did not work and
people were manipulated by other people''s responses. Some women were
not able to get pregnant because of the Covid vaccine. She asked if the
company even gotten the vaccine and stated that she had not, and still
had not got covid. She did not wear a mask nor face wear. Her best
friend received the Covid vaccine and she had died, the vaccine did not
work. Batch/lot number is not provided, and it cannot be obtained.
Follow-up (14Mar2022): This follow-up is being submitted to notify that
the lot/batch number is not available despite the follow-up attempts
made. Follow-up attempts have been completed and no further information
is expected. Follow-up (07Aug2024): This is a follow-up report to notify
that the case 202400232891 and 202200122747 are duplicates. All
subsequent follow-up information will be reported under manufacturer
report number 202400232891.; Reported Cause(s) of Death: Patient died
Result pages: prev 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733
3734 3735 3736 3737 3738 3739 next
New Search
Link To This Search Result:
https://www.medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=3733&VAX=COVID19&DIED=YesCopyright © 2024 National Vaccine Information Center. All rights
reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166
Znamy już efekt szczepień na COVID. WHO opublikowała raport
Re: Znamy już efekt szczepień na COVID. WHO opublikowała raport